


Attorney Docket No.: PR60711USW

**Amendments To The Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

What is claimed is:

1. (Original) A compound of Formula I:



including salts, solvates, and pharmaceutically acceptable derivatives thereof  
wherein

$R^1$  is  $-\text{CH}=\text{CH}-R^5$ ;

$R^5$  is  $-\text{CN}$ ,  $-\text{C}(\text{O})\text{OH}$ ,  $-\text{C}(\text{O})-\text{N}(\text{R}^6)(\text{R}^7)$ ;

$R^6$  and  $R^7$  each independently are hydrogen, alkyl, aryl; or

$R^6$  and  $R^7$  may combine with the nitrogen atom to which they are attached to form a 3 to 7 membered ring, where said ring may be optionally substituted;

each  $R^2$  independently is hydrogen, halogen, haloalkyl, hydroxy, alkoxy, aryloxy, aralkyloxy, alkoxycarbonyloxy, aryloxy carbonyloxy, aralkyloxy carbonyloxy, alkylsulfonyloxy, arylsulfonyloxy, aralkylsulfonyloxy, or acyloxy;

$n$  is 1 or 2;

$R^3$  is hydrogen, hydroxy, alkyl, alkoxy, aryloxy, aralkyloxy, haloalkylsulfonyloxy, halogen, haloalkyl, aryl, heteroaryl, aralkyl, or heteroaralkyl;

$X$  is  $-\text{O}-$ ,  $-\text{S}-$ ,  $-\text{S}(\text{O})-$ , or  $-\text{S}(\text{O})_2-$ ;

each  $R^4$  independently is hydrogen, halogen, haloalkyl, hydroxy, alkoxy, aryloxy, aralkyloxy, alkoxycarbonyloxy, aryloxy carbonyloxy,

Attorney Docket No.: PR60711USW

aralkyloxycarbonyloxy, alkylsulfonyloxy, arylsulfonyloxy, aralkylsulfonyloxy, or acyloxy; and

m is 1 or 2.

2. (Original) The compound of claim 1 wherein  $R^5$  is  $-C(O)OH$  and further comprising wherein the pharmaceutically acceptable derivative is an ester wherein  $R^5$  is  $-C(O)OR^8$  and  $R^8$  is alkyl or aralkyl.
3. (Original) The compound of claim 1 wherein  $R^5$  is  $-C(O)OH$ ,  $-C(O)NH_2$ ,  $-C(O)NH(alkyl)$ ,  $-C(O)N(alkyl)_2$ ,  $-C(O)$ -piperidinyl, or  $-CN$ .
4. (Original) The compound of claim 1 wherein X is O or S.
5. (Original) The compound of claim 4 wherein X is O.
6. (Original) The compound of claim 1 wherein n is 1 and  $R^2$  is hydroxyl, alkoxy, or aralkyloxy.
7. (Original) The compound of claim 6 wherein  $R^2$  is hydroxy substituted on the 7 position of the depicted quinoline ring.
8. (Original) The compound of claim 1 wherein  $R^3$  is alkyl, hydroxyl, aralkyloxy, haloalkylsulfonyloxy, or aryl.
9. (Original) The compound of claim 8 wherein  $R^3$  is  $C_1$ - $C_6$  alkyl or phenyl.
10. (Original) The compound of claim 9 wherein  $R^3$  is ethyl.
11. (Original) The compound of claim 1 wherein m is 1 and  $R^4$  is hydrogen.
12. (Original) The compound of claim 1 wherein m is 1 and  $R^4$  is haloalkyl.
13. (Original) The compound of claim 12 wherein  $R^4$  is  $-CF_3$  and is substituted in the 3 position on the depicted phenyl ring.
14. (Currently Amended) A compound ~~of claim 4~~ selected from the group consisting of:
  - 4-[(7-Hydroxy-2-ethyl-3-phenyl-4-quinolinyloxy)phenyl]-2-propenoic acid;
  - 4-[(7-Hydroxy-2-ethyl-3-phenyl-4-quinolinyloxy)phenyl]-2-propenoamide;
  - 4-[(7-Hydroxy-2-ethyl-3-phenyl-4-quinolinyloxy)phenyl]-2-propeno-N-isopropylamide;

Attorney Docket No.: PR60711USW

4-[(7-Hydroxy-2-ethyl-3-phenyl-4-quinolinyloxyphenyl)-2-propeno-N,N-dimethylamide;

4-[(7-Hydroxy-2-ethyl-3-phenyl-4-quinolinyloxyphenyl)-2-propeno-N-piperidineamide;

4-[(7-Hydroxy-2-ethyl-3-phenyl-4-quinolinyloxyphenyl)-2-propenenitrile;

4-[(7-Hydroxy-2-ethyl-3-(3-trifluoromethylphenyl)-4-quinolinyloxyphenyl)-2-propeno-N-isopropylamide;

4-[(7-Hydroxy-2-ethyl-3-(3-trifluoromethylphenyl)-4-quinolinyloxyphenyl)-2-propenoic acid;

4-[(7-Hydroxy-2-phenyl-3-phenyl-4-quinolinyloxyphenyl)-2-propenoic acid;

3-[(7-Hydroxy-2-ethyl-3-phenyl-4-quinolinyloxyphenyl)-2-propenoic acid; and

4-[(7-Hydroxy-2-ethyl-3-phenyl-4-quinolinyloxyphenyl)-2-propenoamide.

15. (Canceled).

16. (Currently Amended) A pharmaceutical composition comprising a compound according to ~~any one of claims 1 -44~~.

17. (Original) The pharmaceutical composition of claim 16 further comprising a pharmaceutically acceptable excipient, carrier, diluent, or mixtures thereof.

18. (Canceled).

19. (Canceled).

20. (Canceled).

21. (Canceled).

22. (Canceled).

23. (Canceled).

24. (Currently Amended) A method of eliciting a biological or medical response of a tissue, system, animal, or human that responds to selective estrogen receptor modulation in mammals comprising administering to said tissue, system, animal, or human in need of such

Attorney Docket No.: PR60711USW

treatment an effective amount of a compound according to ~~any one of~~ claims 1 -44.

25. (Currently Amended) A method of treating, healing, preventing, ameliorating, or decreasing advancement of a disease, disorder, condition, or side effect that responds to selective estrogen receptor modulation in mammals comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound according to ~~any one of~~ claims 1 -44.
26. (Currently Amended) A method for treating, healing, preventing, ameliorating, or decreasing advancement of prophylaxis or treatment of osteoporosis, bone demineralization, reduced bone mass, density, or growth, osteoarthritis, acceleration of bone fracture repair and healing, acceleration of healing in joint replacement, periodontal disease, acceleration of tooth repair or growth, Paget's disease, osteochondrodysplasias, muscle wasting, the maintenance and enhancement of muscle strength and function, frailty or age-related functional decline ("ARFD"), sarcopenia, chronic fatigue syndrome, chronic myalgia, acute fatigue syndrome, acceleration of wound healing, maintenance of sensory function, chronic liver disease, AIDS, weightlessness, burn and trauma recovery, thrombocytopenia, short bowel syndrome, irritable bowel syndrome, inflammatory bowel disease, Crohn's disease and ulcerative colitis, obesity, eating disorders including anorexia associated with cachexia or aging, hypercortisolism and Cushing's syndrome, cardiovascular disease or cardiac dysfunction, congestive heart failure, high blood pressure, breast cancer, malignant tumor cells including breast, brain, skin, ovary, bladder, lymphatic, liver, kidney, uterine, pancreas, endometrium, lung, colon, and prostate, prostatic hyperplasia, hirsutism, acne, seborrhea, androgenic alopecia, anemia, hyperpilosity, adenomas and neoplasia of the prostate, hyperinsulinemia, insulin resistance, diabetes, syndrome X, dyslipidemia, urinary incontinence, arteriosclerosis, libido enhancement, sexual dysfunction, depression, depressive symptoms, nervousness, irritability, stress, reduced mental energy and low self-

Attorney Docket No.: PR60711USW

esteem, improvement of cognitive function, endometriosis, polycystic ovary syndrome, counteracting preeclampsia, premenstrual syndrome, contraception, uterine fibroid disease, and/or aortic smooth muscle cell proliferation, vaginal dryness, pruritis, dyspareunia, dysuria, frequent urination, urinary tract infections, hypercholesterolemia, hyperlipidemia, peripheral vascular disease, restenosis, vasospasm, vascular wall damage due to immune responses, Alzheimer's disease, bone disease, aging, inflammation, rheumatoid arthritis, respiratory disease, emphysema, reperfusion injury, viral hepatitis, tuberculosis, psoriasis, amyotrophic lateral sclerosis, stroke, CNS trauma, dementia, neurodegeneration, breast pain and dysmenorrhea, menopausal or postmenopausal disorders, vasomotor symptoms, urogenital or vulvar vaginal atrophy, atrophic vaginitis, female sexual dysfunction, for enhancing libido, for the treatment of hypoactive sexual disorder, sexual arousal disorder, for increasing the frequency and intensity of orgasms, vaginismus, osteopenia, endometriosis, BPH (benign prostatic hypertrophy), autoimmune diseases, Hashimoto's thyroiditis, SLE (systemic lupus erythematosus), myasthenia gravis, or reperfusion damage of ischemic myocardium in a mammal comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound according to ~~any one of~~ claims 1 -44.

27. (Original) The method of claim 26 wherein the disease, disorder, condition, or side effect is menopausal or postmenopausal disorders, - vasomotor symptoms, urogenital or vulvar vaginal atrophy, atrophic vaginitis, female sexual dysfunction, breast cancer, depressive symptoms, diabetes, bone demineralization, and/or osteoporosis. osteoporosis, cardiovascular disease, breast cancer, uterine cancer, prostate cancer, dyslipidemia, menopausal vasomotor conditions, central nervous system conditions and disorders, prostate hyperplasia, urinary incontinence, atherosclerosis, uterine fibroid disease, aortic smooth muscle cell proliferation, or endometriosis.